What are the common side effects of irinotecan (Camptosar) and how should they be managed?

Irinotecan Side Effects

Irinotecan causes two distinct types of diarrhea—acute cholinergic diarrhea occurring within 24 hours (treated with atropine) and late-onset diarrhea occurring 6-14 days after administration (the most clinically significant toxicity)—along with neutropenia, nausea/vomiting, and alopecia as the primary adverse effects. 1

Major Side Effects and Their Management

Diarrhea (Most Common and Potentially Life-Threatening)

Two distinct patterns:

• Acute/Early Diarrhea (within 24 hours):

  • Part of a cholinergic syndrome from acetylcholinesterase inhibition 2
  • Accompanied by abdominal cramping, rhinitis, increased salivation, lacrimation, diaphoresis, flushing, and miosis 1
  • Management: Atropine administration effectively controls this syndrome 2

• Late-Onset Diarrhea (median onset 6-14 days):

  • Unpredictable, non-cumulative, occurs at all dose levels 3
  • More common with 3-weekly schedules than weekly dosing 3
  • Can be severe (grade 3/4) in up to 40% of patients 2
  • May be watery or bloody 3
  • Critical risk: When diarrhea coincides with neutrophil nadir, gut barrier disruption can lead to overwhelming sepsis and death 3
  • Management: High-dose loperamide at first sign of loose stools; octreotide LAR 30 mg for refractory cases 4

Hematologic Toxicity

• Neutropenia: Common and dose-limiting
• Grade 3/4 neutropenia risk varies significantly by UGT1A1 genotype 5
• Increased infection risk, especially when concurrent with diarrhea 3

Gastrointestinal Effects Beyond Diarrhea

• Nausea and vomiting (common) 1
• Abdominal pain 1
• Anorexia 1
• Constipation (less common) 1

Other Common Side Effects

• Alopecia 1, 6
• Fatigue/Asthenia 1
• Fever 1

Serious but Less Common Toxicities

• Hepatotoxicity: Hepatic function abnormalities in 3% of patients 1
• Pulmonary toxicity: Dyspnea, cough 1
• Cardiovascular: Edema (4%), hypertension 1

Critical Risk Factors for Increased Toxicity

Patients at highest risk require dose reduction:

• UGT1A1 polymorphisms: Homozygous *28 or *6 variants have dramatically increased risk of severe diarrhea and neutropenia 4, 7, 5

  • Recommendation: 30% dose reduction at Cycle 1 for poor metabolizers 7
  • UGT1A1*6 shows significant differences in delayed diarrhea (p=0.000), leukopenia (p=0.003), and neutropenia (p=0.000) risk 5

• Hepatic dysfunction: Dose adjustment required based on degree of impairment 4

• Previous chemotherapy-induced diarrhea 3

• Unresected primary tumor 3

• Female gender 3

Frequency in Combination Regimens

Grade 3/4 diarrhea rates vary by regimen 3:

• CapeIRI: 47%
• FOLFOXIRI: 20%
• FOLFIRI: 14%

Key Management Principles

Immediate intervention is critical: Patients must be educated to start high-dose loperamide (4 mg initially, then 2 mg every 2 hours until 12 hours diarrhea-free) at the first sign of loose stools to prevent life-threatening complications 6. Delay in treatment can lead to severe dehydration, electrolyte imbalances, renal impairment, and sepsis, particularly in neutropenic patients 3.

Monitoring requirements:

• Neutrophil counts before each cycle
• Immediate evaluation if diarrhea develops with fever or neutropenia
• Liver function tests if hepatic symptoms develop 1

Drug Interactions

Critical interaction: Itraconazole and other strong CYP3A4 inhibitors increase irinotecan plasma concentrations, potentially causing fatal adverse events 1. Avoid concomitant use.